The Potential of Flavonoids and Flavonoid Metabolites in the Treatment of Neurodegenerative Pathology in Disorders of Cognitive Decline

被引:32
作者
Melrose, James [1 ,2 ,3 ]
机构
[1] Univ Sydney, Inst Bone & Joint Res, Kolling Inst Med Res, Fac Hlth & Sci,Royal North Shore Hosp,Raymond Purv, St Leonards, NSW 2065, Australia
[2] Univ NSW, Grad Sch Biomed Engn, Sydney, NSW 2052, Australia
[3] Univ Sydney, Sydney Med Sch, Royal North Shore Hosp, Northern Campus, St Leonards, NSW 2065, Australia
关键词
therapeutic treatment of neurological disorders; gut-brainaxis; protocatechuic acid; urolithins; gamma-valerolactones; autism; bipolar disorder; Alzheimer's disease; Parkinson's disease; VAGUS NERVE-STIMULATION; TRADITIONAL CHINESE MEDICINE; BRAIN-BARRIER DISRUPTION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; GUT MICROBIOTA; PROLYL OLIGOPEPTIDASE; ANXIOLYTIC-LIKE; DOUBLE-BLIND; EPIGALLOCATECHIN-3-GALLATE EGCG;
D O I
10.3390/antiox12030663
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Flavonoids are a biodiverse family of dietary compounds that have antioxidant, anti-inflammatory, antiviral, and antibacterial cell protective profiles. They have received considerable attention as potential therapeutic agents in biomedicine and have been widely used in traditional complimentary medicine for generations. Such complimentary medical herbal formulations are extremely complex mixtures of many pharmacologically active compounds that provide a therapeutic outcome through a network pharmacological effects of considerable complexity. Methods are emerging to determine the active components used in complimentary medicine and their therapeutic targets and to decipher the complexities of how network pharmacology provides such therapeutic effects. The gut microbiome has important roles to play in the generation of bioactive flavonoid metabolites retaining or exceeding the antioxidative and anti-inflammatory properties of the intact flavonoid and, in some cases, new antitumor and antineurodegenerative bioactivities. Certain food items have been identified with high prebiotic profiles suggesting that neutraceutical supplementation may be beneficially employed to preserve a healthy population of bacterial symbiont species and minimize the establishment of harmful pathogenic organisms. Gut health is an important consideration effecting the overall health and wellbeing of linked organ systems. Bioconversion of dietary flavonoid components in the gut generates therapeutic metabolites that can also be transported by the vagus nerve and systemic circulation to brain cell populations to exert a beneficial effect. This is particularly important in a number of neurological disorders (autism, bipolar disorder, AD, PD) characterized by effects on moods, resulting in depression and anxiety, impaired motor function, and long-term cognitive decline. Native flavonoids have many beneficial properties in the alleviation of inflammation in tissues, however, concerns have been raised that therapeutic levels of flavonoids may not be achieved, thus allowing them to display optimal therapeutic effects. Dietary manipulation and vagal stimulation have both yielded beneficial responses in the treatment of autism spectrum disorders, depression, and anxiety, establishing the vagal nerve as a route of communication in the gut-brain axis with established roles in disease intervention. While a number of native flavonoids are beneficial in the treatment of neurological disorders and are known to penetrate the blood-brain barrier, microbiome-generated flavonoid metabolites (e.g., protocatechuic acid, urolithins, ?-valerolactones), which retain the antioxidant and anti-inflammatory potency of the native flavonoid in addition to bioactive properties that promote mitochondrial health and cerebrovascular microcapillary function, should also be considered as potential biotherapeutic agents. Studies are warranted to experimentally examine the efficacy of flavonoid metabolites directly, as they emerge as novel therapeutic options.
引用
收藏
页数:47
相关论文
共 47 条
  • [31] Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action
    Zirak, Nahid
    Shafiee, Mojtaba
    Soltani, Ghasem
    Mirzaei, Mohammad
    Sahebkar, Amirhossein
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (06) : 8496 - 8508
  • [32] Effectiveness of sorting tests for detecting cognitive decline in older adults with dementia and other common neurodegenerative disorders: A meta-analysis
    Foran, A. M.
    Mathias, J. L.
    Bowden, S. C.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2021, 120 : 442 - 454
  • [33] Treatment of hypertension and obstructive sleep apnea counteracts cognitive decline in common neurocognitive disorders in diagnosis-related patterns
    Kujovic, Milenko
    Lipka, Tim
    Zalman, Mark
    Baumann, Leonie
    Jaenner, Michaela
    Baumann, Bruno
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [34] Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology
    Orciani, Chiara
    Do Carmo, Sonia
    Foret, Morgan K.
    Hall, Helene
    Lavagna, Agustina
    Bonomo, Quentin
    Huang, Chunwei
    Cuello, A. Claudio
    NEUROBIOLOGY OF AGING, 2023, 132 : 220 - 232
  • [35] The potential of xanthotoxin in the treatment of cognitive disorders: current insights and future perspectives
    Agarwal, Uma
    Pannu, Arzoo
    Tonk, Rajiv Kumar
    Jaiswal, Puja
    Jain, Kajal
    FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 10 (01)
  • [36] A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment
    Guyot, Anne-Cecile
    Leuxe, Charlotte
    Disdier, Clemence
    Oumata, Nassima
    Costa, Narciso
    Le Roux, Gwenaelle
    Varela, Paloma F.
    Duchon, Arnaud
    Charbonnier, Jean Baptiste
    Herault, Yann
    Pavoni, Serena
    Galons, Herve
    Andriambeloson, Emile
    Wagner, Stephanie
    Meijer, Laurent
    Lund, Amie K.
    Mabondzo, Aloise
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [37] Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development
    Dexter, Emily
    Kong, Qingzhong
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2021, 21 (09) : 983 - 991
  • [38] Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part I. a literature review
    Dexter, Emily
    Kong, Qingzhong
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2021, 21 (09) : 969 - 982
  • [39] Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
    Pelle, Maria Chiara
    Zaffina, Isabella
    Giofre, Federica
    Pujia, Roberta
    Arturi, Franco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [40] ABT-089: Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders
    Rueter, LE
    Anderson, DJ
    Briggs, CA
    Donnelly-Roberts, DL
    Gintant, GA
    Gopalakrishnan, M
    Lin, NH
    Osinski, MA
    Reinhart, GA
    Buckley, MJ
    Martin, RL
    McDermott, JS
    Preusser, LC
    Seifert, TR
    Su, Z
    Cox, BE
    Decker, MW
    Sullivan, JP
    CNS DRUG REVIEWS, 2004, 10 (02): : 167 - 182